Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05086497 · ClinicalTrials.gov registry record · NA
WBSI Guided Personalized Delivery of TTFields
A NA study of GBM and Glioma Glioblastoma Multiforme, sponsored by Abramson Cancer Center at Penn Medicine.
- Recruiting
- Registry status
- NA
- Development phase
- 155
- Enrollment target
- 2
- Study locations
NCT05086497: Recruiting NA study of GBM and Glioma Glioblastoma Multiforme, sponsored by Abramson Cancer Center at Penn Medicine.
NCT05086497 is a NA study of GBM and Glioma Glioblastoma Multiforme that is actively recruiting participants, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 155 participants, above the 107-participant average among 24 other GBM trials with a reported enrollment target (45% higher). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05086497, a NA study of GBM and Glioma Glioblastoma Multiforme, is actively recruiting participants, sponsored by Abramson Cancer Center at Penn Medicine.
- RECRUITING
- Registry status
- NA
- Development phase
- 155 participants
- Enrollment target
- 2
- Study locations
Study Summary
This research study is for Glioblastoma (GBM) patients who will be beginning Optune as part of their clinical care, which is a novel treatment that utilizes - tumor treating fields (TTFields), (aka, electrical therapy), which has shown to improve overall survival in large multi-center trials. As a part of this study, participants will either receive Optune with "standard array mapping" (based on regular contrast enhanced MRI) or an "alternative (more precise) array mapping" based on sophisticated state of the art MRI techniques including "whole brain spectroscopy". Whole brain MRI spectroscopy provides additional metabolic information to map out the full extent of tumor spreading within the brain (far beyond from what is seen on regular MRI), by identifying certain metabolites that are present in cancer cells versus healthy tissue. This study is being performed to show whether alternative array mapping improves treatment outcomes, as opposed to the standard array mapping, by maximizing delivery of TTFields dose, thereby achieving more effective tumor cell killing, decreasing the rate of local recurrence, and improving the overall survival as well as quality of life measures.
Primary Outcome
Using whole brain spectroscopy imaging, diffusion and perfusion MR imaging, a combined multiparametric approach will be utilized to compare treatment response from patients enrolled in two study arms.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Whole Brain Spectroscopy Imaging Array Mapping Layout
Study Locations (2)
Pennsylvania
- Abramson Cancer Center - Philadelphia
- Penn Medicine, University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2023-01-15 |
| Est. Completion | 2026-06-30 |
| Phase | NA |
What NCT05086497 shows while recruiting
NCT05086497 is an interventional study that assigns participants to a tested intervention. The registered 155 participants enrollment target is mid-sized for trials with a published cap, above the 107-participant average among 24 other GBM trials with a reported enrollment target (45% higher).
The record links to 3 conditions, with GBM appearing as the primary indexed condition, and to 1 intervention - of which Whole Brain Spectroscopy Imaging Array Mapping Layout is the first listed.
NCT05086497 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05086497 about?
NCT05086497 is a clinical study titled "WBSI Guided Personalized Delivery of TTFields". This research study is for Glioblastoma (GBM) patients who will be beginning Optune as part of their clinical care, which is a novel treatment that utilizes - tumor treating fields (TTFields), (aka, electrical therapy), which has shown to improve overall survival in large multi-center trials. As a p...
What is the current status of trial NCT05086497?
This trial is currently recruiting. It is a NA study. The enrollment target is 155 participants. The study started on 2023-01-15. Estimated completion is 2026-06-30.
What conditions does trial NCT05086497 study?
This clinical trial studies the following conditions: GBM, Glioma Glioblastoma Multiforme, Tumor, Brain.
What interventions are being tested in trial NCT05086497?
The interventions under investigation include: Whole Brain Spectroscopy Imaging Array Mapping Layout (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05086497?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05086497 being conducted?
This trial has 2 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for GBM
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05086497's enrollment target sits among peer trials
155 6th of 24 higher than 19 of 24 other GBM trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other GBM trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM)
RECRUITING · NA
-
Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma
RECRUITING · NA
-
Surgical Tissue Flap to Bypass the Blood Brain Barrier in GBM
ACTIVE NOT RECRUITING · NA
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03223610 · 155 participants · Phase 1
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
- NCT05072483 · 155 participants
Natural History Study of CADASIL
- NCT05412069 · 155 participants · NA
Trial to Evaluate Fecobionics in Fecal Incontinence (FI) (NORMAL and ABNORMAL-FI)
- NCT05796531 · 155 participants · NA
Therapeutic Evaluative Conditioning to Reduce Adolescents' Self-injurious Thoughts and Behaviors During and After Psychiatric Inpatient Hospitalization
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI